---

$8.13

+0.1100 ( +1.37% ) 293.4K

Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Type: All Buy Sale Start date: End date: Filter Reset

Date	Type	Amount Purchased	Purchaser
2025-09-24	Buy	30000.00	Morrison Briggs
2025-09-24	Buy	30000.00	Morrison Briggs
2024-06-26	Sale	-61409.00	Saik Andrew
2024-02-27	Sale	-5750.00	Loomis David K
2024-02-27	Sale	-39250.00	Taylor Ian